凝血因子VIII:新兴A型血友病疗法的生物学基础
本文综述凝血因子VIII(FVIII)的生物学基础及其对A型血友病(HA)新兴疗法的推动作用,涵盖FVIII分泌途径、与血管性血友病因子相互作用、FIXa辅因子活性、活化FVIII灭活调控及免疫原性,并介绍FVIII模拟双特异性抗体、重组腺相关病毒(rAAV)载体基因治疗及功能获得性FVIII变体的开发现状。
要点
- 活化FVIII与活化FIX(FIXa)在阴离子膜上结合形成内源性Xase酶复合物,负责在持续凝血的限速步骤中激活FX。
- FVIII模拟双特异性抗体和重组腺相关病毒(rAAV)载体基因治疗已获监管批准用于A型血友病。
- 旨在改善分泌的功能获得性FVIII变体已纳入第二代rAAV载体并近期进入临床试验。
核心结论
- 对FVIII生物学的持续深入理解与A型血友病治疗进展相互促进,是实现血友病治疗终极目标所必需的:使止血正常化并以最小治疗负担优化全球所有患者的健康福祉。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 活化FVIII与活化FIX(FIXa)在阴离子膜上结合形成内源性Xase酶复合物,负责在持续凝血的限速步骤中激活FX。
- A型血友病和B型血友病分别由FVIII和FIX活性遗传性缺陷所致。
- 过去十年A型血友病治疗受益于对FVIII生物学的更深入理解,包括其分泌途径、循环中与血管性血友病因子的相互作用、FIXa辅因子活性的生化本质、活化FVIII经灭活途径的调控及其令人意外的免疫原性。
- FVIII模拟双特异性抗体和重组腺相关病毒(rAAV)载体基因治疗等几种新治疗模式近期获监管批准用于A型血友病。
- 旨在改善分泌的功能获得性FVIII变体已纳入第二代rAAV载体并近期进入临床试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coagulation factor VIII (FVIII) is essential for hemostasis. After activation, it combines with activated FIX (FIXa) on anionic membranes to form the intrinsic Xase enzyme complex, responsible for activating FX in the rate-limiting step of sustained coagulation. Hemophilia A (HA) and hemophilia B are due to inherited deficiencies in the activity of FVIII and FIX, respectively. Treatment of HA over the last decade has benefited from an improved understanding of FVIII biology, including its secretion pathway, its interaction with von Willebrand factor in circulation, the biochemical nature of its FIXa cofactor activity, the regulation of activated FVIII by inactivation pathways, and its surprising immunogenicity. This has facilitated biotechnology innovations with first-in-class examples of several new therapeutic modalities recently receiving regulatory approval for HA, including FVIII-mimetic bispecific antibodies and recombinant adeno-associated viral (rAAV) vector-based gene therapy. Biological insights into FVIII also guide the development and use of gain-of-function FVIII variants aimed at addressing the limitations of first-generation rAAV vectors for HA. Several gain-of-function FVIII variants designed to have improved secretion are currently incorporated in second-generation rAAV vectors and have recently entered clinical trials. Continued mutually reinforcing advancements in the understanding of FVIII biology and treatments for HA are necessary to achieve the ultimate goal of hemophilia therapy: normalizing hemostasis and optimizing well-being with minimal treatment burden for all patients worldwide.
引用
- Samelson-Jones BJ, Doshi BS, George LA, et al. Coagulation factor VIII: biological basis of emerging hemophilia A therapies. Blood. 2024. PMID: 39088776. doi:10.1182/blood.2023023275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。